NMDA glutamate receptors are strongly implicated in neurodegenerative diseases,78 and comprise the drug target of memantine, the first non-cholinesterase inhibitor FDA-approved AD drug.79 Interference of the DLGAP1–DLC2 interaction inhibits NMDA receptor activity in dendritic spines.80 In turn, synaptic activity-induced DLGAP1–DLC2 interaction in dendritic spines stabilizes the scaffolding complex and enhances the NMDA currents.81, 82. The gene discussed is DLGAP1; the disease is Alzheimer disease.